Skip to main content
AMCP Nexus 2024 Main banner
Back

Drugs, Diseases, and the Managed Care Impact

(D5) Advancing Schizophrenia Management Strategies in the Patient Journey: Treatment Innovations, Adherence, and Health Outcomes

Wednesday, October 16, 2024
2:30 PM – 3:45 PM PT
Location: 121
CPE
ACPE UAN:0233-0000-24-059-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
This activity is supported by an independent medical education grant from Bristol Myers Squibb.

Considering the complexities of managing schizophrenia in the United States, this session addresses the disease of schizophrenia from the patient, clinical expert, and managed care pharmacist perspective.

A comprehensive review of the clinical aspects of schizophrenia, focusing on its prevalence, diagnosis, progression, complications, and treatment challenges, will be provided, as well as the managed care strategies essential for improving access, adherence, and health outcomes for individuals with schizophrenia. Faculty will emphasize the unique challenges faced by at-risk populations, particularly within diverse and underserved communities, and explore the economic impact of treatment-resistant and poorly controlled schizophrenia.

Keeping the patient at the forefront, the audience will hear from a patient who will describe her journey leading to diagnosis and treatment and address the disease burden, factors influencing adherence and quality of life considerations related to treatment.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Describe the lived experience of patients with schizophrenia, including factors that impact medication adherence and quality of life.
  2. Distinguish the new and emerging therapies for schizophrenia, including clinical efficacy, safety, and adherence considerations.
  3. Discuss managed care opportunities to support patients with schizophrenia to improve adherence, and health outcomes.